Automation and High-Throughput Protein Production
Learn how laboratory automation supports reproducible protein workflows, improves throughput, and accelerates process development.
Discover automation solutionsProtein Production Workflow and Process for Life Sciences
Published: September 8, 2026
Protein production is the process of generating proteins through genetic engineering and recombinant expression systems. This workflow includes the selection of appropriate genetic components followed by cultivation, screening, and optimization.10 This ensures reproducible and scalable results across laboratory and industrial environments.
Key Takeaways
- Protein production uses recombinant expression systems to generate proteins for research, biotechnology and biopharmaceutical applications.
- Recombinant protein production includes gene cloning, host-cell transformation, protein expression and downstream purification.
- Multiple expression hosts can be used, including bacteria, yeast, insect cells, mammalian cells, plants and animals.
- Scalable recombinant DNA technologies enable consistent protein manufacturing with improved quality, safety and production efficiency.
Why Protein Production Matters
Proteins have various applications as food alternatives like plant-based (soy, lectin), animal-based (casein, collagen), as enzymes (amylase) and peptides in chemistry and biotechnology, as therapeutic proteins (insulin) in biopharmaceuticals, and biomaterials for bioactive compounds delivery vehicles via the oral route.18 For all the above, the required protein from an external source is needed on a large scale to meet growing demand. Large-scale production of proteins also offers many opportunities for economic growth.10
What Is Recombinant Protein Production
Recombinant protein production is the process of generating proteins, where the target gene is cloned into an expression vector and transferred into a suitable host to enable controlled protein synthesis. It allows the large-scale production of proteins that may be difficult or impossible to obtain from natural sources. The overall process typically involves gene cloning, host-cell transformation or transfection, protein expression, and downstream purification to obtain a functional protein with improved protein yield, quality, and scalability.
Various hosts of prokaryote and eukaryote origin have been explored in the search for a viable expression of human proteins, including:
| Expression Host | Example |
|---|---|
| Bacteria |
E. coli: Insulin19 |
| Yeast |
Saccharomyces cerevisiae: Hepatitis B Vaccine15 |
| Insect Cells |
Spodoptera frugiperda (Sf9 cells) using baculovirus expression system: Cervarix® HPV Vaccine12 |
| Mammalian Cells |
Chinese hamster ovary cells: Erythropoietin4,19 |
| Plants |
Solanum tuberosum Agrobacterium-mediated transformation: Human Serum Albumin22 |
| Animals |
Transgenic dairy goats: Human Antithrombin8 |
Table 1. Common expression hosts used for recombinant protein production and representative recombinant protein products.
Protein production at a glance:
Recombinant DNA technology enables scalable protein manufacturing by combining genetic engineering, optimized expression hosts and downstream purification processes to produce high-quality proteins.
Benefits of Scalable Protein Production Systems
Recombinant DNA technology has transformed protein production systems by enabling the scalable, reproducible, and consistent manufacture of therapeutic proteins. Its advantages have made it a cornerstone of modern protein manufacturing and biopharmaceutical development.
Advantages of Producing Proteins Using Recombinant DNA Technology
High Biological Activity
Recombinant DNA technology enables the production of proteins encoded by human genes, reducing the likelihood of immune reactions, and ensuring high biological activity.
Scalable Manufacturing
Therapeutic proteins can be manufactured efficiently and at a large scale, making the production process economically viable.
Improved Safety
It minimizes the risk of contamination and transmission of known or unknown pathogens that may be present in animal- or human-derived sources.
Enhanced Performance
Recombinant proteins can be engineered to enhance their specificity, extend their half-life, and improve their overall therapeutic performance.
Targeted Protein Engineering
This technology allows precise genetic modifications, facilitating the development of proteins with improved activity, stability, and target selectivity.
View References
- Alhammad LA, Ainosah TK, Ahmad AM et al. (2023). The impact of laboratory automation on efficiency and accuracy in healthcare settings. International Journal Of Community Medicine And Public Health, 11(1), 459–463.
- Bhatwa A, Wang W, Hassan YI et al. (2021). Challenges Associated With the Formation of Recombinant Protein Inclusion Bodies in Escherichia coli and Strategies to Address Them for Industrial Applications. Frontiers in Bioengineering and Biotechnology. 9:630551.
- Blass E, Ott PA. (2021). Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nature Reviews Clinical Oncology. 18, 215–229.
- Cha H, Park J-H. (2021). Recombinant Human Erythropoietin Production in Chinese Hamster Ovary Cells Is Enhanced by Supplementation of α-Helix Domain of 30Kc19 Protein. Applied Sciences. 11(22):11009.
- Chabot et al. (2026). Development of a recombinant membrane protein ELISA for analyzing antibody responses against SARS-CoV-2 envelope proteins. Journal of Biological Chemistry. Volume 302(1).
- Chen Y-L, Xie X-X, Zhong N et al. (2023). Research Progresses and Applications of Fluorescent Protein Antibodies: A Review Focusing on Nanobodies. International Journal of Molecular Sciences. 24(5):4307.
- Creangă EC, Stan R, Nicolae AC et al. (2025). Personalized Therapeutic Advances in Erythropoietin Signaling: From Anemia Management to Extensive Clinical Applications. Pharmaceutics. 17(9):1190.
- Echelard Y, Meade HM, Ziomek CA. (2006). Production of Recombinant Therapeutic Proteins in the Milk of Transgenic Animals. BioPharm International. 19(8).
- Gupta V, Sengupta M, Prakash J et al. (2017). Production of Recombinant Pharmaceutical Proteins. In: Basic and Applied Aspects of Biotechnology. Springer, Singapore.
- Gupta V et al. (2016). Production of Recombinant Pharmaceutical Proteins. Basic and Applied Aspects of Biotechnology. 77–101.
- Hernandez SI, Berezin CT, Miller KM et al. (2024). Sequencing Strategy to Ensure Accurate Plasmid Assembly. ACS Synthetic Biology. 13(12):4099-4109.
- Hong M, Li T, Xue W et al. (2022). Genetic engineering of baculovirus-insect cell system to improve protein production. Frontiers in Bioengineering and Biotechnology. 10:994743.
- Hou L, Zhang XY, Li Y et al. (2016). Rapid Screening of Recombinant Plasmids by Direct Colony Quantitative Real-Time PCR. Advances in Bioscience and Biotechnology. 7, 428-433.
- Beckman Coulter. Nanoliter-Scale DNA Assembly with the Echo 525 Liquid Handler Application Note.
- Jayakrishnan A, Wan Rosli WR, Tahir ARM et al. (2024). Evolving Paradigms of Recombinant Protein Production in Pharmaceutical Industry: A Rigorous Review. Sci. 6(1):9.
- Kumar V, Barwal A, Sharma N et al. (2024). Therapeutic proteins: developments, progress, challenges, and future perspectives. 3 Biotech. 14, 112.
- Mahmood F, Xu R, Awan MUN et al. (2023). HBV Vaccines: Advances and Development. Vaccines. 11(12):1862.
- Martins JT, Bourbon AI, Pinheiro AC et al. (2018). Protein-Based Structures for Food Applications: From Macro to Nanoscale. Frontiers in Sustainable Food Systems. 2:77.
- Ojima-Kato T. (2025). Advances in recombinant protein production in microorganisms and functional peptide tags. Bioscience, Biotechnology, and Biochemistry. 89(1).
- Pastores GM. (2010). Recombinant Glucocerebrosidase (Imiglucerase) as a Therapy for Gaucher Disease. BioDrugs. 24, 41–47.
- Rosano GL, Morales ES, Ceccarelli EA. (2019). New tools for recombinant protein production in Escherichia coli: A 5-year update. Protein Science. 28(8):1412-1422.
- Shanmugaraj B, Bulaon CJI, Phoolcharoen W. (2020). Plant Molecular Farming: A Viable Platform for Recombinant Biopharmaceutical Production. Plants. 9(7):842.
- Shilling PJ, Mirzadeh K, Cumming AJ et al. (2020). Improved designs for pET expression plasmids increase protein production yield in Escherichia coli. Communications Biology. 3, 214.
- Wang W. (2015). Advanced protein formulations. Protein Science. 24(7):1031-9.
- Wu et al. (2025). Automating an Adeno-associated Virus (AAV) Functional Assay Using the Biomek i7 Liquid Handler with Integrated Vi-CELL BLU Analyzer. Application Note.
- Swain SM, Shastry M, Hamilton E. (2023). Targeting HER2-positive breast cancer: advances and future directions. Nature Reviews Drug Discovery. 22(2):101-126.
- Konkle B, Oldenburg J, Pasi J et al. (2023). Prophylaxis with a recombinant factor VIII Fc in hemophilia A: long-term follow-up on joint health, efficacy, and safety from phase 3 studies in children and adults.
- Gao Y, Yin Y, Xie P et al. (2025). Interferon in Liver Diseases: Recent Advances. Advances in Therapy. 42, 4210–4223.
Explore Related Protein Production Topics
Continue exploring the technologies, workflows, and applications that support efficient and scalable recombinant protein production.
FAQ on Protein Production Workflow and Process
Which protein expression system is best for scalability and post-translational modifications?
The best expression system depends on the required yield, scalability, cost, and post-translational modifications (PTMs).
- E. coli offers rapid, low-cost, high-yield production but lacks complex PTMs.
- Yeast provides good scalability with some eukaryotic PTMs.
- Insect cells support improved protein folding and PTMs.
- Mammalian cells (CHO, HEK293) are preferred for therapeutic proteins requiring human-like PTMs and glycosylation.15
How do you scale protein production from research to manufacturing?
Scaling protein production from research to manufacturing requires the systematic optimization of expression systems, cell culture processes, purification workflows, and quality control strategies to maintain protein yield, quality, and consistency as production volumes increase.
Automation plays a key role in successful scale-up by reducing manual variability, standardizing workflows, and enabling high-throughput screening of clones, media, and process conditions.1
